Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions

The ROS1 tyrosine kinase inhibitor (TKI) crizotinib has shown dramatic effects in patients with non‐small cell lung cancer (NSCLC) harboring ROS1 fusion genes. However, patients inevitably develop resistance to this agent. Therefore, a new treatment strategy is required for lung tumors with ROS1 fus...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Sci
Main Authors: Kato, Yuka, Ninomiya, Kiichiro, Ohashi, Kadoaki, Tomida, Shuta, Makimoto, Go, Watanabe, Hiromi, Kudo, Kenichiro, Matsumoto, Shingo, Umemura, Shigeki, Goto, Koichi, Ichihara, Eiki, Ninomiya, Takashi, Kubo, Toshio, Sato, Akiko, Hotta, Katsuyuki, Tabata, Masahiro, Toyooka, Shinichi, Maeda, Yoshinobu, Kiura, Katsuyuki
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2018
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6172052/
https://ncbi.nlm.nih.gov/pubmed/30053332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13752
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items